Nanjing, China

Peng Lyu

This inventor holds 1 USPTO granted patent. Top assignee: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Active years: 2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Peng Lyu. Retrieved from https://idiyas.com/inventor/peng-lyu-6shbf36e

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 14.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Peng Lyu

Introduction

Peng Lyu is a notable inventor based in Nanjing, China. He has made significant strides in the field of pharmaceuticals, particularly in developing therapeutic combinations for cancer treatment. His work is characterized by a focus on innovative solutions that address critical health challenges.

Latest Patents

Peng Lyu holds a patent for a therapeutic combination of a quinoline derivative and an antibody. This patent, which includes an immune checkpoint inhibitor and a tyrosine kinase inhibitor, demonstrates promising activity against lung tumors and liver tumors. The combination is designed to enhance the efficacy of cancer treatments, showcasing Lyu's commitment to advancing medical science.

Career Highlights

Lyu is affiliated with Chia Tai Tianqing Pharmaceutical Group Co., Ltd., where he contributes to research and development efforts. His role in the company allows him to collaborate with other talented professionals in the pharmaceutical industry.

Collaborations

Some of his notable coworkers include Xin Tian and Chen Shen, who work alongside him in various projects aimed at improving therapeutic options for patients.

Conclusion

Peng Lyu's innovative work in the pharmaceutical field exemplifies the impact of dedicated inventors on healthcare advancements. His contributions continue to pave the way for new treatment options that can significantly improve patient outcomes.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…